Illustration showing immunomodulators that latch onto the PD-L1 cancer cells and the PD-1 immune cells to block the liaison PD-L1 PD-1 which dampens the immune response to the tumor. When the immune cell recognizes the cancer cell, it can control it (1). But the PD-L1 receptors on the surface of the cancer cell, related to the PD-1 receptors of the immune cells slow down the immune response (2). The anti-PD-L1 and anti-PD-1 immunomodulators latch onto the corresponding receptors and block the liaison between these two receptors (3), blocking the dampening of the immune response.